MaxCyte reports preliminary FY2022 revenue $44.3M (+31% YoY); guides 2023 growth 21-26%

MAXCYTE, INC.

FY2022 total revenue ~$44.3M, up 31% from $33.9M in 2021; Q4 revenue ~$12.4M, up 22%.
Installed base >600 instruments (vs >500 end 2021); 18 SPL partnerships at year-end, 19 after Jan 2023.
2023 guidance: total revenue growth 21-26%, core growth 20-25%, SPL program-related revenue ~$6M.
Potential pre-commercial milestones under SPLs >$1.55B; 16 licensed clinical programs in clinic.
SPL program-related revenue in FY2022 was $4.6M vs $2.5M in 2021; Q4 included $1.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.